Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
138,547,005
-
Share change
-
+3,227,056
-
Total reported value
-
$4,404,414,365
-
Put/Call ratio
-
189%
-
Price per share
-
$31.79
-
Number of holders
-
123
-
Value change
-
+$104,896,124
-
Number of buys
-
67
-
Number of sells
-
53
Institutional Holders of CEREVEL THERAPEUTICS HLDNG I - COM (CERE) as of Q2 2023
As of 30 Jun 2023,
CEREVEL THERAPEUTICS HLDNG I - COM (CERE) was held by
123 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
138,547,005 shares.
The largest 10 holders included
Bain Capital Investors LLC, FMR LLC, PERCEPTIVE ADVISORS LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., STATE STREET CORP, Rock Springs Capital Management LP, Paradigm Biocapital Advisors LP, and T. Rowe Price Investment Management, Inc..
This page lists
123
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.